However, it has been shown that melanoma-reactive CTLs established from the tumor-infiltrating lymphocytes (TILs) of HLA-A*2402-positive patients recognize a non-mutated peptide, encoded by an aberrant transcript of the gp100 gene [25]. This evidence concerns the gene PMEL and melanoma.